Reframing the Definition of Obesity
Sabina Paglialunga, PhD Senior Director, Scientific Affairs Two notable guidance documents addressin...
Blog
GLP-1 Agonist-Induced Delayed Gastric Emptying – A Clinical...
 Your browser does not support the audio element. ⬇ Download MP3 By Sabina Paglialunga, PhD & A...
Blog
How Healthy Volunteer Studies can Accelerate Oncology Drug D...
By Sabina Paglialunga, PhD & Aernout van Haarst, PhD; Senior Directors Scientific Affairs, Celer...
Blog
Key Clinical Pharmacology Studies to Support Biologic Drug R...
By Sabina Paglialunga, PhDÂ & Aernout van Haarst, PhD; Senior Directors Scientific Affairs, Cele...
Blog
12 Questions to Help Guide Renal Impairment PK Study Design
By Sabina Paglialunga, PhDÂ Director Scientific Affairs, Celerion Need to run a renal impairment pha...
Blog
Adaptive Trial Designs
Flexibility of Adaptive Early Phase Study Designs Sabina Paglialunga, PhD Â Director, Scientific Aff...
Blog
A Decade of Innovative Technology to Accelerate Drug Develop...
Celerion continues its Celebration of Translating Science into Medicine for over a decade by highlig...
Blog
The Platforms and Promise of COVID-19 Vaccines
 by Sabina Paglialunga, PhD -  Director, Scientific Affairs, Celerion COVID-19 is a highly infectio...
Blog
Celebrating a Decade of Biosimilars Development
Biosimilars are not an exact copy but are similar to the originally approved biological product. Fol...